Immune Therapeutics

OverviewSuggest Edit

Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of its novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. Company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK).
TypePublic
Founded2012
HQWinter Park, FL, US
Websiteimmunetherapeutics.com

Latest Updates

Employees (est.) (Feb 2019)4(-60%)
Revenue (FY, 2018)$113.5 K(+3178%)
Share Price (Jan 2021)$0
Cybersecurity ratingBMore

Key People/Management at Immune Therapeutics

Peter Aronstram

Peter Aronstram

CFO

Immune Therapeutics Office Locations

Immune Therapeutics has offices in Winter Park and Orlando
Winter Park, FL, US (HQ)
2431 Aloma Ave #124
Orlando, FL, US
37 N Orange Ave #607
Show all (2)

Immune Therapeutics Financials and Metrics

Immune Therapeutics Revenue

Immune Therapeutics's revenue was reported to be $113.50 k in FY, 2018
USD

Net income (Q2, 2020)

(803.5k)

EBIT (Q2, 2020)

(18.0k)

Market capitalization (22-Jan-2021)

8.0m

Closing stock price (22-Jan-2021)

0.0

Cash (30-Jun-2020)

45.3k

EV

13.5m
Immune Therapeutics's current market capitalization is $8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

16.2k3.5k113.5k

Revenue growth, %

(79%)

Cost of goods sold

47.7k

Gross profit

65.8k
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.1k5.6k5.0k3.5k65.0k

Cost of goods sold

33.2k

Gross profit

31.8k

Gross profit Margin, %

49%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

406.6k192.0k23.1k74.4k14.7k5.9k4.9k

Accounts Receivable

16.2k

Prepaid Expenses

215.9k30.0k

Inventories

178.1k82.8k
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

176.2k231.5k207.7k233.7k58.7k58.6k30.9k22.4k153.9k132.8k64.3k22.2k98.1k45.0k22.6k30.4k5.9k5.7k21.4k6.5k6.2k45.3k

Accounts Receivable

2.1k7.7k12.7k19.7k2.7k

Prepaid Expenses

130.0k30.9k45.0k42.5k35.0k49.7k30.0k30.0k45.4k1.6k11.3k

Inventories

214.3k158.6k158.6k158.6k82.8k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(106.1m)(49.9m)(16.9m)(19.8m)(7.9m)(8.6m)(3.4m)

Depreciation and Amortization

2.9m2.9m594.8k1.6k826.01.7k2.1k

Inventories

(178.1k)95.3k82.8k

Accounts Payable

553.2k1.8m900.5k541.0k919.1k341.6k895.0k
USDQ1, 2013

Financial Leverage

1.1 x
Show all financial metrics

Immune Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Immune Therapeutics Online and Social Media Presence

Embed Graph

Immune Therapeutics News and Updates

Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change

ORLANDO, Fla., Oct. 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies for the treatment of cancer using an immune therapy and a…

Immune Therapeutics Today Announces Appointment of Michael K. Handley as its new Chief Executive Officer and Member of the Board of Directors

ORLANDO, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and infla…

Immune Therapeutics, Inc. Provides Shareholder Update on 14A

ORLANDO, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, ca…

Immune Therapeutics welcomes Kevin Phelps to Board of Directors

ORLANDO, Fla., Jan. 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune Therapeutics”, “IMUN” or the “Company”), a late stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory…

Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors

ORLANDO, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and infla…

Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board

ORLANDO, Fla., Aug. 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune Therapeutics", "IMUN" or the "Company"), a late stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory…

Immune Therapeutics Blogs

Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19

ORLANDO, Florida, March 20, 2020 – Immune Therapeutics, Inc. (OTC: IMUN) (“Immune” “IMUN” or the “Company”), Immune Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and …

COVID19 Virus Concept Sheet

Immune Therapeutics (OTC: IMUN) and its partner, Cytocom Inc., are focused on immune modulation for the treatment of cancer, autoimmune diseases and viral infections. One of our late-stage drugs, Lodonal™, has been safely and successfully used in human clinical trials to treat cancer, Crohn’s diseas…

Immune Therapeutics, Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

Immune Therapeutics, Inc. Files Amendment on 1000 to 1 Reverse and Name Change with the State of Florida Division of Corporations. Awaiting Completion of FINRA Approval Process Orlando, Florida--(Newsfile Corp. - March 9, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "C…

Immune Therapeutics, Inc. Appoints New Independent Director

Fort Collins, Co., February 18, 2020 —Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced the appointment of Mr. M…

Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

Orlando, Florida--(Newsfile Corp. - February 11, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announ…

Immune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company

ORLANDO, Fla., Dec. 16, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune", “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a privately held development-stage oncology therapeutics company, today announced that Immune will acquire Ale…
Show more

Immune Therapeutics Frequently Asked Questions

  • When was Immune Therapeutics founded?

    Immune Therapeutics was founded in 2012.

  • Who are Immune Therapeutics key executives?

    Immune Therapeutics's key executives are Peter Aronstram.

  • How many employees does Immune Therapeutics have?

    Immune Therapeutics has 4 employees.

  • Who are Immune Therapeutics competitors?

    Competitors of Immune Therapeutics include Celyad, ANI Pharmaceuticals and Catalyst Pharmaceuticals.

  • Where is Immune Therapeutics headquarters?

    Immune Therapeutics headquarters is located at 2431 Aloma Ave #124, Winter Park.

  • Where are Immune Therapeutics offices?

    Immune Therapeutics has offices in Winter Park and Orlando.

  • How many offices does Immune Therapeutics have?

    Immune Therapeutics has 2 offices.